Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of General Medicine
- Vol. ume 14, 347-356
- https://doi.org/10.2147/ijgm.s287506
Abstract
Purpose: To investigate the potential of maximum standardized uptake value (SUVmax) in predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients. Methods: Clinical data of 311 NSCLC patients who had undergone both EGFR mutation test and 18F-FDG PET/CT scans between January 2013 and December 2017 at our hospital were retrospectively analyzed. Patients were sub-grouped by their origin of SUVmax. Univariate and multivariate analyses were performed to investigate the association between clinical factors and EGFR mutations. Receiver operating characteristic curve (ROC) analysis was performed to confirm the predictive value of clinical factors. In vitro experiments were performed to confirm the correlation between EGFR mutations and glycolysis. Results: EGFR-mutant patients had higher SUVmax than the wild-type patients in both primary tumors and metastases. In the multivariate analysis, SUVmax, gender and histopathologic type were determined as independent predictors of EGFR mutation status for patients whose SUVmax were obtained from the primary tumors; while for patients whose SUVmax were obtained from the metastases, SUVmax, smoking status and histopathologic type were regarded as independent predictors. ROC analysis showed that SUVmax of the primary tumors (cut off > 10.92), not of the metastases, has better predictive value than other clinical factors in predicting EGFR mutation status. The predict performance was improved after combined SUVmax with other independent predictors. In addition, our in vitro experiments demonstrated that lung cancer cells with EGFR mutations have higher aerobic glycolysis level than wild-type cells. Conclusion: SUVmax of the primary tumors has the potential to serve as a biomarker to predict EGFR mutation status in NSCLC patients.Keywords
This publication has 31 references indexed in Scilit:
- Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinomaCritical Reviews in Oncology/Hematology, 2013
- EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?Lung Cancer: Targets and Therapy, 2013
- FDG‐PET SUV‐max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinomaRespirology, 2013
- [18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer TherapyMedical Principles and Practice, 2013
- Expression of STAT3 in non-small cell lung cancer and its clinical significanceAdvances in Lung Cancer, 2013
- Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumoursEuropean Radiology, 2010
- 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysisLung Cancer, 2010
- Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell LinesPLOS ONE, 2009
- Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinomaMedical Oncology, 2009